Evidence map›Paper›PMID 41035422›Full record

ArticleMolecular therapy. Oncology2025

CircSPINT2 confers sensitivity to osimertinib via hsa-miR-1296-3p/RBP1 axis and inhibits NSCLC progression.

Nalini Devi Verusingam, Aliaksandr A Yarmishyn, Min-Long Tsai, Ping-Hsing Tsai, Yi-Chen Chen, Chih-Ling Yeh, Soon-Keng Cheong, Po-Kuei Hsu, Shih-Hwa Chiou, Alan Han-Kiat Ong and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nalini Devi VerusingamDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Aliaksandr A YarmishynDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Min-Long TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Ping-Hsing TsaiDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Yi-Chen ChenDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Chih-Ling YehDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Soon-Keng CheongDepartment of Research & Development, Nasional Cancer Council (MAKNA), Kuala Lumpur, Malaysia.
Po-Kuei HsuDepartment of Surgery, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Shih-Hwa ChiouDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.
Alan Han-Kiat OngDepartment of Pre-Clinical Sciences, M. Kandiah Faculty of Medicine and Health Sciences, Universiti Tunku Abdul Rahman, Selangor, Malaysia.
Mong-Lien WangDepartment of Medical Research, Taipei Veterans General Hospital, Taipei 112, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the most common type of lung cancer. Prolonged treatment of LUAD with 1

Indexed as

biomarkercircular RNAEGFR-TKIL858Rlung cancernon-coding RNANSCLCosimertinibosimertinib-resistantT790M

Identifiers

PMID41035422
PMCPMC12481618

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.